Q2 EPS Estimate for Foghorn Therapeutics Lowered by Analyst

Foghorn Therapeutics Inc. (NASDAQ:FHTX) – B. Riley dropped their Q2 2025 earnings per share (EPS) estimates for Foghorn Therapeutics in a note issued to investors on Wednesday, May 14th. B. Riley analyst K. Patel now forecasts that the company will post earnings of ($0.36) per share for the quarter, down from their prior forecast of ($0.32). B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for Foghorn Therapeutics’ current full-year earnings is ($1.55) per share. B. Riley also issued estimates for Foghorn Therapeutics’ Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($1.49) EPS, FY2026 earnings at ($1.44) EPS and FY2027 earnings at ($1.89) EPS.

Foghorn Therapeutics (NASDAQ:FHTX) last released its earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.30). The business had revenue of $5.95 million during the quarter, compared to the consensus estimate of $4.96 million.

Several other research firms have also recently weighed in on FHTX. JMP Securities restated a “market outperform” rating and set a $9.00 price target on shares of Foghorn Therapeutics in a report on Thursday, May 15th. Citizens Jmp initiated coverage on Foghorn Therapeutics in a report on Wednesday, April 23rd. They set a “mkt outperform” rating and a $9.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $13.00 price target on shares of Foghorn Therapeutics in a report on Wednesday, April 30th. Finally, Citigroup assumed coverage on Foghorn Therapeutics in a report on Wednesday, April 23rd. They set an “outperform” rating on the stock. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $12.13.

Foghorn Therapeutics Stock Down 5.0%

Foghorn Therapeutics stock opened at $4.21 on Monday. The stock has a market cap of $234.67 million, a PE ratio of -2.19 and a beta of 3.13. The business’s 50-day moving average price is $3.97 and its two-hundred day moving average price is $5.11. Foghorn Therapeutics has a 12-month low of $2.94 and a 12-month high of $10.25.

Hedge Funds Weigh In On Foghorn Therapeutics

Several institutional investors have recently added to or reduced their stakes in FHTX. Barclays PLC lifted its stake in Foghorn Therapeutics by 191.6% in the third quarter. Barclays PLC now owns 39,920 shares of the company’s stock valued at $371,000 after buying an additional 26,228 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in Foghorn Therapeutics in the fourth quarter valued at approximately $56,000. Wingate Wealth Advisors Inc. acquired a new position in shares of Foghorn Therapeutics during the fourth quarter worth approximately $134,000. Rhumbline Advisers raised its position in shares of Foghorn Therapeutics by 9.1% during the fourth quarter. Rhumbline Advisers now owns 36,384 shares of the company’s stock worth $172,000 after purchasing an additional 3,049 shares during the period. Finally, Los Angeles Capital Management LLC acquired a new position in shares of Foghorn Therapeutics during the fourth quarter worth approximately $75,000. 61.55% of the stock is owned by institutional investors and hedge funds.

Foghorn Therapeutics Company Profile

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.